Cargando…

Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach

This study analyzes the impact of COVID-19 full vaccination shocks on the US stock market in the period January 14, 2021– August 20, 2021. Using the Nonlinear Autoregressive Distributed Lag model, we find that the positive and negative COVID-19 full vaccination growth shocks have a positive and symm...

Descripción completa

Detalles Bibliográficos
Autores principales: Atri, Hanen, Teka, Hanen, Kouki, Saoussen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080858/
https://www.ncbi.nlm.nih.gov/pubmed/37057049
http://dx.doi.org/10.1016/j.heliyon.2023.e15332
_version_ 1785021003293786112
author Atri, Hanen
Teka, Hanen
Kouki, Saoussen
author_facet Atri, Hanen
Teka, Hanen
Kouki, Saoussen
author_sort Atri, Hanen
collection PubMed
description This study analyzes the impact of COVID-19 full vaccination shocks on the US stock market in the period January 14, 2021– August 20, 2021. Using the Nonlinear Autoregressive Distributed Lag model, we find that the positive and negative COVID-19 full vaccination growth shocks have a positive and symmetrical impact on the US stock market over the long run. Additionally, the short-run findings provide that the US stock market reacts negatively with delay to the positive and negative COVID-19 full vaccination growth shocks. The study findings provide good insights that COVID-19 full vaccination immunizes accordingly to the S&P 500 index in the long run. The study results indicate that the impact of positive and negative COVID-19 full vaccination growth shocks on the stock market in the short run differs from that in the long run. This research bears important implications: governments should implement preventive measures with vaccination to recover the stock market. Policy makers ought to urge adopting policy measures to reduce panic and boost investor confidence during economic and health crises.
format Online
Article
Text
id pubmed-10080858
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100808582023-04-07 Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach Atri, Hanen Teka, Hanen Kouki, Saoussen Heliyon Research Article This study analyzes the impact of COVID-19 full vaccination shocks on the US stock market in the period January 14, 2021– August 20, 2021. Using the Nonlinear Autoregressive Distributed Lag model, we find that the positive and negative COVID-19 full vaccination growth shocks have a positive and symmetrical impact on the US stock market over the long run. Additionally, the short-run findings provide that the US stock market reacts negatively with delay to the positive and negative COVID-19 full vaccination growth shocks. The study findings provide good insights that COVID-19 full vaccination immunizes accordingly to the S&P 500 index in the long run. The study results indicate that the impact of positive and negative COVID-19 full vaccination growth shocks on the stock market in the short run differs from that in the long run. This research bears important implications: governments should implement preventive measures with vaccination to recover the stock market. Policy makers ought to urge adopting policy measures to reduce panic and boost investor confidence during economic and health crises. Elsevier 2023-04-07 /pmc/articles/PMC10080858/ /pubmed/37057049 http://dx.doi.org/10.1016/j.heliyon.2023.e15332 Text en © 2023 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Atri, Hanen
Teka, Hanen
Kouki, Saoussen
Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach
title Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach
title_full Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach
title_fullStr Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach
title_full_unstemmed Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach
title_short Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach
title_sort does us full vaccination against covid-19 immunize correspondingly s&p500 index: evidence from the nardl approach
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080858/
https://www.ncbi.nlm.nih.gov/pubmed/37057049
http://dx.doi.org/10.1016/j.heliyon.2023.e15332
work_keys_str_mv AT atrihanen doesusfullvaccinationagainstcovid19immunizecorrespondinglysp500indexevidencefromthenardlapproach
AT tekahanen doesusfullvaccinationagainstcovid19immunizecorrespondinglysp500indexevidencefromthenardlapproach
AT koukisaoussen doesusfullvaccinationagainstcovid19immunizecorrespondinglysp500indexevidencefromthenardlapproach